Indian Opposition Leader Denounces Ranbaxy Merger With Japanese Multi-national

by Gopalan on  June 23, 2008 at 11:09 AM Corporate News
  •   Print
  •   Share
  •   Comments
  •  Text 
Lal Kishen Advani, leader of the Bharatiya Janata Party and a possible Prime Ministerial candidate after next year’s national elections, has denounced the merger of the Ranbaxy Laboratories, Indian pharma major with a Japanese MNC as unacceptable.

The news of the merger of the Ranbaxy with Japan's Daiichi Sankyo took the market by storm last fortnight. The firm’s founders sold away their entire stake, 34.82 per cent.

Ranbaxy is the largest Indian pharmaceutical company, and it has aggressively pursued the generic route in drug manufacturing – that is targeting drugs whose patents have expired.

A generic drug product is one that is comparable to an innovator drug product in dosage form, strength, route of administration, quality, performance characteristics and intended use.

Since it is cheaper to produce generics and one doesn’t have to invest in research much, pharmaceutical firms in countries like India plump for such a product line. Ranbaxy too made its fortunes that way.

But globally things are changing. Innovator drug companies are fiercely protecting their drugs through litigation or by extending the life on an existing drug patent. What with WTO and the like, the climate for generic firms is changing even in India.

It was in such circumstances that Ranbaxy is changing hands, but many an Indian observer is aghast, as is L.K.Advani, a senior opposition figure.

“It's a cause for worry that an Indian company, known for its research and development capabilities and operating in a critical area like pharmaceuticals, has lost its identity to a foreign company," he said, while participating in a function in Mumbai Saturday.

Page 1 Page 1 | 2  Next
 Email Email   RSS Feeds RSS Feeds   Print this page Print   Save this page Save   Link Link   Syndicate Syndicate   Comments Comments   Bookmark and Share
 
Comment & Contribute
Comments should be on the topic and should not be abusive. Comments are normally moderated and are reviewed after they are posted.
* Your comment can be maximum of 2500 characters

Notify me when reply is posted
I agree to the terms and conditions
  
If you have a question about health related issues, you can now post it in our Ask An Expert section on our community website Medwonders.com and get answers from our panel of experts.
X

Medwonders Health Network

  • Health News Index
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Archive
Date :
Category :
Keyword :
  • News Quick Links
News Central Health Watch
Latest Health News Health In Focus
News Category (500+) Breaking Health News
Popular News Celebrating Life
Health News and Press Release Medindia - Exclusive
News Photo Gallery India Special
News Video Gallery Lifestyle and Wellness
News From Other Resources
News Categories:  
Diabetes Health Center

Corporate Related News

» Sun Pharma’s ANDA for Azelastine Nasal Spray Gets FDA Nod » Mylan’s ANDA for Clopidogrel Tablets Gets FDA Approval
» Drug Marketing: Abbott Labs Fined $1.6 Billion » The Cancer Cell Line Encyclopedia Launched by Novartis
» LeGoo Maker Pluromed to be Acquired by Sanofi » NGOs Protest Against Novartis' Glivec Lawsuit in India
» Allscripts Expanding India Operations » Bio-Tech Medicine Proves to be Attractive for TCG Lifesciences
Read More >>